AbbVie PE Ratio 2010-2018 | ABBV

Current and historical PE ratio for AbbVie (ABBV) from 2010 to 2018. The price to earnings or PE ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. The current PE ratio for AbbVie (ABBV) as of March 31, 2018 is 14.56.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $92.417B $28.216B
AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie aims to help patients' live healthier lives and collaborate on sustainable healthcare solutions.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $337.885B 16.15
Pfizer (PFE) United States $222.399B 13.69
Novartis AG (NVS) Switzerland $187.250B 16.06
Merck (MRK) United States $168.539B 15.06
Novo Nordisk (NVO) Denmark $121.712B 20.17
Sanofi (SNY) France $105.114B 13.31
GlaxoSmithKline (GSK) United Kingdom $100.888B 13.79
Eli Lilly (LLY) United States $97.070B 19.27
AstraZeneca (AZN) United Kingdom $93.793B 9.82
Bristol-Myers Squibb (BMY) United States $92.417B 18.18